SCHEMBL2169993

SCHEMBL2169993

CCOC(=O)C(C)ON=Cc1cc(Br)c(Oc2ccc(OC)c(C(=O)c3ccc(Cl)cc3)c2)c(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
MAPT P10636 7/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 3/20 0.38
LMNA P02545 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
TNFRSF1A P19438 1/20 0.37
HSD11B1 P28845 1/20 0.37
PTPN1 P18031 1/20 0.36
ABCG2 Q9UNQ0 2/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16496417 1.00 POLB (0.48) POLBMAPTNPSR1HTTALDH1A1
SCHEMBL16496563 0.90 THRB (0.38) POLBMAPTNPSR1LMNAMEN1
SCHEMBL2169679 0.90 THRB (0.38) POLBMAPTNPSR1LMNAMEN1
SCHEMBL2170699 0.83 TNFRSF1A (0.40) POLBMAPTHTTALDH1A1LMNA
SCHEMBL2170701 0.83 TNFRSF1A (0.40) POLBMAPTHTTALDH1A1LMNA
SCHEMBL16496217 0.82 THRB (0.46) MAPTLMNATNFRSF1A
SCHEMBL2170309 0.82 THRB (0.46) MAPTLMNATNFRSF1A
SCHEMBL16495901 0.81 TNFRSF1A (0.39) POLBMAPTHTTALDH1A1LMNA
SCHEMBL16496483 0.81 THRB (0.37) LMNAKMT2AKDM4EHPGD
SCHEMBL2169568 0.81 THRB (0.37) LMNAKMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA POLB 3792/4885MAPT 692/4885NPSR1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.